Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer - Concepedia

Concepedia

Publication | Open Access

Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer

DOI Full Paper Access

127

Citations

18

References

2021

Year

David M. O’Malley, Ana Oaknin, Bradley J. Monk, Frédèric Selle, Carlos A. Rojas, Laurence Gladieff, Dominique Berton, Alexandra Léary, Kathleen N. Moore, Maria Del Pilar Estevez-Diz,

Gynecologic Oncology

Abstract

Balstilimab demonstrated meaningful and durable clinical activity, with manageable safety, in patients with previously-treated, recurrent/metastatic cervical cancer.

References

	Year	Citations

Page 1